case

From Japan to Denmark: Medical Incubator Japan invests in Hoba Therapeutics

case

From Japan to Denmark: Medical Incubator Japan invests in Hoba Therapeutics

Medical Incubator Japan, a venture capital firm headquartered in Japan specialising in biotech sector investments across the EU, Japan, and the US, has recently made an investment in the Danish company Hoba Therapeutics. Hoba Therapeutics is dedicated to developing innovative biopharmaceuticals for the relief, prevention, and treatment of chronic pain and hearing loss.

When

This financing round was jointly led by Indaco Venture Partners and Medical Incubator Japan, with contributions from existing investors including Novo Holdings, Eir Ventures, and the Export and Investment Fund of Denmark (EIFO). The Series A financing has reached a first close of EUR 23 million (USD 25 million) in total. Additionally, it includes funding from The European Innovation Council Fund as part of the Accelerator funding program under Horizon Europe.

The funds raised in the Series A first close will enable Hoba Therapeutics to progress HB-086 through late pre-clinical development and into Phase 1 clinical studies in patients suffering from painful Chemotherapy-Induced Peripheral Neuropathy (CIPN). HB-086 is being developed by Hoba Therapeutics for the treatment of chronic neuropathic pain conditions.

Why Medical Incubator Japan chose a Danish company

Their investment portfolio encompasses pharmaceuticals, medical devices, diagnostics, and cutting-edge life science technologies driven by AI. Although their history is relatively concise, they currently manage approximately USD 50 M in assets.

Dr. Kenji Harada, Investment Officer at Medical Incubator Japan, expressed his excitement about the investment in Hoba, a Danish innovation: 

“It’s a great honour for us to take a co-lead position in this round. I firmly believe that Hoba Therapeutics’ programs will yield significant positive impacts on pain management and related therapies. This investment in an outstanding Danish company not only signifies our support, but also paves the way for future investments from Japan into Danish and other European biotech companies.”

Dr. Kenji Harada

Investment Officer at Medical Incubator Japan

Our team at Invest in Denmark has been supporting the investment case by proving Medical Incubator Japan the data helpful for the investment analyses.

“We have chosen Denmark because we found it a good innovation centre, and there is strong support from the government and other private companies, including Novo Nordisk. The entire system surrounding the medical sector is wonderful.”

Dr. Kenji Harada

Investment Officer at Medical Incubator Japan

Get in touch

Want to join or invest in the Danish life science industry?

We provide free-of-charge confidential and tailor-made solutions for foreign companies looking to set up a new business in Denmark or expand an existing one. Please contact one of our experts here:  

Copenhagen

  • Sarina Lohmann

    Title: Special Advisor – Maritime and transport – Analysis & Partnerships

    Area: Copenhagen

    Phone: +4533920423

Berlin

Kolding

Silkeborg

Aarhus

Aalborg

Oslo

London

Paris

Munich

New-York

Toronto

Silicon-Valley

Tokyo

Bangalore

Taipei

Shanghai

Singapore